Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety and efficacy study of evinacumab in homozygous familial hypercholesterolemia
2017-003170-13Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of evinacumab in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Primary endpoint: Primary safety endpoint. Started Jan 2018; status: completed.
02
Drugs
evinacumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)hypercholesterolemia
Beyond the preview
Go deeper on 2017-003170-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003170-13.